肝动脉化疗栓塞术联合中药治疗中晚期肝癌的临床研究

Clinical efficacy of transcatheter artery chemoembolization combined traditional Chinese medicine for the treatment of primary liver cancer

目的:探讨中药联合TACE治疗中晚期肝癌的临床疗效。方法:将105例肝癌患者随机分为研究组和对照组,研究组43例,行TACE时灌注中药艾迪注射液50ml,术后第10天均口服复方斑蝥胶囊及鸦胆子油口服液;对照组62例,仅行TACE术。对2组患者的生存率、生活质量进行随访。结果:研究组和对照组患者术后6、12、24、36个月生存率分别为88.37%、81.4%、61.52%、39.53%与85.74%、73.02%、58.73%、33.33%;研究组生存率高于对照组,有一定的生存优势,生存期内研究组生活质量明显好于对照组。结论:中药联合TACE治疗中晚期肝脏恶性肿瘤可改善机体免疫功能,减轻化疗药不良反应,明显延长患者的生存期,提高患者的生活质量。

Objective： To evaluate clinical efficacy of transcatheter artery chemoembolization combined traditional chinese medicine for the treatment of primary liver cancer. Methods： 105 patients with primary liver cancer,who had lost opportunity of operation,were divided into the research group and control group randomly, with 43 patients in research group and 63patients in control group. 43 patients of the research group were treated by TACE with Aidi zhusheye,and 10 days later were treated by Fu fang ban mao capsules plus Yadanziyou Koufu Ruye. The control group was treated only by TACE. Both groups were followed up at 6,12,24,36months. Results：The research group and control group 6 m,12 m,24 m,36 m survival rates were 88.37%, 81.4%,61.52%,39.53% and 85.74%,73.02%,58.73%,33.33%,respectively. The research group was better than control group. Conclusion：Transcatheter artery chemoembolization combined traditional chinese medicine can improve organic immunologic function, ease the side reaction of chemo-medicine, prolong patients＇ duration,improve the quality of life.